PMID- 22895833
OWN - NLM
STAT- MEDLINE
DCOM- 20131219
LR  - 20161020
IS  - 1439-7609 (Electronic)
IS  - 1439-7595 (Linking)
VI  - 23
IP  - 3
DP  - 2013 May
TI  - Twenty-four-week clinical results of adalimumab therapy in Japanese patients with 
      rheumatoid arthritis: retrospective analysis for the best use of adalimumab in 
      daily practice.
PG  - 466-77
LID - 10.1007/s10165-012-0705-y [doi]
AB  - OBJECTIVE: We evaluated patient drug adherence to and efficacy and safety of 
      adalimumab (ADA) based on data collected from approximately 200 patients to 
      retrospectively examine the best use of ADA in Japanese patients with 
      longstanding rheumatoid arthritis (RA) managed in daily practice. METHODS: For 
      explorative comparisons, patients were stratified by prior use or no use of 
      biologics (Bio-naive vs. Bio-switch) and concomitant use (+) or no use (-) of 
      methotrexate (MTX) into four subgroups. The primary efficacy endpoint was extent 
      of improvement in the Disease Activity Score in 28 joints using erythrocyte 
      sedimentation rate (DAS28-ESR) from baseline to 24 weeks assessed as European 
      League Against Rheumatism (EULAR) good response. Secondary endpoints included ADA 
      treatment continuation as represented by Kaplan-Meier survival curves and 
      percentages of patients achieving remission as defined by DAS28-ESR <2.6. 
      RESULTS: Overall, mean DAS28-ESR significantly decreased from 5.6 +/- 1.2 at 
      baseline to 4.1 +/- 1.7 at week 24 (p < 0.0001), and >30 % of patients achieved 
      EULAR good response. Subgroup analyses indicated that patients in the Bio-naive 
      and MTX (+) subgroup showed the highest EULAR good response rate of 37.3 % at 
      week 24. The three most commonly reported adverse events (AEs) were skin 
      allergies such as injection-site reactions, infections, and respiratory disorders 
      such as interstitial lung lesions and organizing pneumonia. CONCLUSION: In 
      conclusion, ADA therapy resulted in significant clinical response in established 
      Japanese patients with RA treated in daily practice. It also demonstrated 
      generally good safety and tolerability. It was suggested that the best use of ADA 
      may be in biologically naive patients with concomitant administration of MTX.
FAU - Kaneko, Atsushi
AU  - Kaneko A
AD  - Department of Orthopaedic Surgery and Rheumatology, National Hospital 
      Organization Nagoya Medical Center, 4-1-1 Sannomaru, Naka-ku, Nagoya 460-0001, 
      Japan. a-kaneko@xj.commufa.jp
FAU - Hirano, Yuji
AU  - Hirano Y
FAU - Fujibayashi, Takayoshi
AU  - Fujibayashi T
FAU - Hattori, Yosuke
AU  - Hattori Y
FAU - Terabe, Kenya
AU  - Terabe K
FAU - Kojima, Toshihisa
AU  - Kojima T
FAU - Ishiguro, Naoki
AU  - Ishiguro N
LA  - eng
PT  - Journal Article
DEP - 20120816
PL  - England
TA  - Mod Rheumatol
JT  - Modern rheumatology
JID - 100959226
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - FYS6T7F842 (Adalimumab)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Adalimumab
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized/adverse effects/*therapeutic use
MH  - Antirheumatic Agents/adverse effects/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Japan
MH  - Longitudinal Studies
MH  - Male
MH  - Medication Adherence
MH  - Methotrexate/adverse effects/therapeutic use
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Treatment Outcome
EDAT- 2012/08/17 06:00
MHDA- 2013/12/20 06:00
CRDT- 2012/08/17 06:00
PHST- 2012/03/01 00:00 [received]
PHST- 2012/06/04 00:00 [accepted]
PHST- 2012/08/17 06:00 [entrez]
PHST- 2012/08/17 06:00 [pubmed]
PHST- 2013/12/20 06:00 [medline]
AID - 10.1007/s10165-012-0705-y [doi]
PST - ppublish
SO  - Mod Rheumatol. 2013 May;23(3):466-77. doi: 10.1007/s10165-012-0705-y. Epub 2012 
      Aug 16.